Literature DB >> 3861322

Pharmacokinetics of ceftizoxime.

U Gundert-Remy, R Hildebrandt, A Stiehl, P Schlegel.   

Abstract

The kinetics of ceftizoxime, a newly developed cephalosporin, were evaluated in 6 healthy subjects, with respect to its excretory pathways especially by the biliary route. Total, renal and biliary clearance were determined at two different steady states. Steady state was achieved by constant intravenous infusion (604.1 mg/h) over 6 h after an initial loading dose (750 mg); 1.5 h after discontinuation of that infusion, a further infusion was commenced at a lower rate (284 mg/h) over 3 h, the second steady state being reached 0.5 to 1.0 h later. The drug was mainly excreted by the kidneys (56.7 to 92.9% of the dose). Biliary excretion, measured by the duodenal perfusion and marker dilution technique, was low (0.2 to 7.8% of the dose). Urinary and biliary excretion as well as total clearance were not dose-dependent. However, there was pronounced interindividual variation in total (35.2 to 236 ml/min) and renal clearance (10.6 to 208 ml/min), which could both be explained by varying interindividual urinary flow rates (mean flow rate: 0.99 ml/min to 3.14 ml/min). Intraindividual variation in renal clearance was less pronounced, but in the same subject changes in renal clearance were correlated with changes in urinary flow rate. From the varying renal clearance, which exceeded the glomerular filtration rate at high urinary flow rates and was below it at low urinary flow rates, it can be concluded that, in addition to glomerular filtration, tubular secretion and tubular reabsorption are involved in the renal excretion of ceftizoxime.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3861322     DOI: 10.1007/bf00544368

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Pharmacokinetics, protein binding, and extravascular distribution of ceftizoxime in normal subjects.

Authors:  L R Peterson; D N Gerding; L L Van Etta; J H Eckfeldt; T A Larson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

3.  Role of serum protein binding and multiple antibiotic doses in the extravascular distribution of ceftizoxime and cefotaxime.

Authors:  D N Gerding; L L Van Etta; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

4.  Renal excretion of cephapirin and cephaloridine: evidence for saturable tubular reabsorption.

Authors:  A Arvidsson; O Borgå; G Alván
Journal:  Clin Pharmacol Ther       Date:  1979-06       Impact factor: 6.875

5.  Elimination of bacteria in biliary tract infections during ceftizoxime therapy.

Authors:  E B Helm; D Wurbs; R Haag; D Bentele; P M Shah
Journal:  Infection       Date:  1982       Impact factor: 3.553

6.  Ceftizoxime kinetics and renal handling.

Authors:  J Dubb; P Actor; D Pitkin; F Alexander; R Familiar; S Ehrlich; R Stote
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

7.  Phase I study of ceftizoxime, a new cephalosporin. Single-dose study.

Authors:  N Nakashima; K Suzuki; H Hashimoto; K Nishijima
Journal:  J Clin Pharmacol       Date:  1981-10       Impact factor: 3.126

8.  Elimination kinetics of ceftizoxime in humans with and without renal insufficiency.

Authors:  M Ohkawa; A Okasho; T Sugata; K Kuroda
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

9.  Estimation of biliary excretion of ureidopenicillins in healthy volunteers using marker dilution technique.

Authors:  U Gundert-Remy; F Frohnapfel; W Jourdan; E Weber; A Stiehl
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

  9 in total
  1 in total

Review 1.  Pharmacological properties of cephalosporins.

Authors:  W Christ
Journal:  Infection       Date:  1991       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.